The commercial market for priority review vouchers

Health Affairs

Volumn 35, Issue 5, 2016, Pages 776-783

  Ridley, David B ^a   Régnier, Stephane A ^b  

^a DUKE UNIVERSITY   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; NEW DRUG;

ARTICLE; COMMERCIAL PHENOMENA; COMPETITION; CONSUMER; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HUMAN; NEGLECTED DISEASE; PRIORITY REVIEW VOUCHER; PURCHASING; REIMBURSEMENT; DRUG APPROVAL; DRUG MANUFACTURE; ECONOMIC ASPECT; ECONOMICS; LEGISLATION AND JURISPRUDENCE; MOTIVATION; ORGANIZATION AND MANAGEMENT; PROCEDURES; TIME FACTOR; TRENDS; UNITED STATES;

DRUG APPROVAL; DRUG INDUSTRY; ECONOMIC COMPETITION; HUMANS; MOTIVATION; NEGLECTED DISEASES; ORPHAN DRUG PRODUCTION; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84969190329     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2015.1314     Document Type: Article

References (30)

1. Ridley DB, Grabowski HG, Moe JL. Developing drugs for developing countries. Health Aff (Millwood). 2006;25(2):313-24.
2. Gans JS, Ridley DB. Innovation incentives under transferable fasttrack regulatory review. J Ind Econ. 2013;61(3):789-816.
3. Stefanakis R, Robertson AS, Ponder EL, Moree M. Analysis of neglected tropical disease drug and vaccine development pipelines to predict issuance of FDA priority review vouchers over the next decade. PLoS Negl Trop Dis. 2012;6(10):e1803.
4. Ridley DB. Priority review voucher [Internet]. Durham (NC): Duke University; 2016 Jan 8 [cited 2016 Mar 23]. Available from: http:// priorityreviewvoucher.org
5. Berndt ER, Glennerster R, Kremer MR, Lee J, Levine R, Weizsäcker G, et al. Advance market commitments for vaccines against neglected diseases:estimating costs and effectiveness. Health Econ. 2007;16(5):491-511.
6. Towse A, Keuffel E, Kettler HE, Ridley DB. Drugs and vaccines for developing countries. In: Danzon PM, Nicholson S, editors. The Oxford handbook of the economics of the biopharmaceutical industry. New York (NY): Oxford University Press; 2012. p. 1-39.
7. Hensley S. Price rises for ticket to a quicker drug review by FDA. National Public Radio [serial on the Internet]. 2015 Aug 19 [cited 2016 Mar 23]. Available from: http:// www.npr.org/sections/healthshots/2015/08/19/432887081/ price-rises-for-ticket-to-a-quickerdrug- review-by-fda
8. Noor W. Placing value on FDA's priority review vouchers. In Vivo. 2009;27(8):1-8.
9. Matheny J, Smith B, Courtney B, Mair M. Drug and vaccine development for infectious diseases: the value of priority review vouchers. Clin Pharmacol Ther. 2009;85(6):571-2.
10. Robertson AS, Stefanakis R, Josepn D, Moree M. The impact of the US priority review voucher on privatesector investment in global health research and development. PLoS Negl Trop Dis. 2012;6(8):e1750.
11. Ridley DB, Sánchez AC. Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases. Lancet. 2010;376(9744):922-7.
12. Régnier SA, Ridley DB. Market watch: forecasting market share in the US pharmaceutical market. Nat Rev Drug Discov. 2015;14(9):594-5.
13. Grabowski HG, Ridley DB, Moe JL. Priority review vouchers to encourage innovation for neglected diseases. In: Eggleston K, editor. Prescribing cultures and pharmaceutical policy in the Asia-Pacific. Washington (DC): Brookings Institution Press; 2009. p 347-65.
14. Jenkins JK. CDER new drug review:2012 update [Internet]. Silver Spring (MD): Food and Drug Administration; [cited 2016 Mar 23]. Available from: http://www.fda.gov/ downloads/AboutFDA/Centers Offices/OfficeofMedicalProduct sandTobacco/CDER/UCM331454.pdf
15. Matheny J, Mair M, Smith B. Cost/ success projections for US biodefense countermeasure development. Nat Biotechnol. 2008;26(9):981-3.
16. SDI Health is now part of IMS Health. For information about the National Prescription Audit, see IMS Institute for Healthcare Informatics. National Prescription Audit [Internet]. Collegeville (PA): IMS Health; [cited 2016 Mar 23]. (HRSN Data Brief). Available from: http:// www.imshealth.com/files/web/ IMSH%20Institute/NPA_Data_ Brief-.pdf
17. Berndt ER, Nass D, Kleinrock M, Aitken M. Decline in economic returns from new drugs raises questions about sustaining innovations. Health Aff (Millwood). 2015;34(2):245-52.
18. To access the Appendix, click on the Appendix link in the box to the right of the article online.
19. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20-33.
20. Mintz J, Chen D (University of Calgary, AB). The U.S. corporate effective tax rate: myth and the fact [Internet]. Washington (DC): Tax Foundation; 2014 Feb [cited 2016 Mar 23]. (Special Report No. 214). Available from: http://tax foundation.org/sites/tax foundation.org/files/docs/ SR214.pdf
21. Grabowski HG, Ridley DB, Schulman KA. Entry and competition in generic biologics. Manage Decis Econ. 2007; 28(4-5):439-51.
22. Winslow R, Walker J. Drug firms buy $67.5 million voucher to speed FDA review. Wall Street Journal. 2014 Jul 30.
23. Grabowski HG, Long G, Mortimer R. Recent trends in brand-name and generic drug competition. J Med Econ. 2014;17(3):207-14.
24. Huet N. Sanofi cholesterol drug touted as potential $3 billion blockbuster. Reuters [serial on the Internet]. 2013 Sep 25 [cited 2016 Mar 29]. Available from: http:// www.reuters.com/article/us-sanoficholesterol- idUSBRE98O0SX 20130925
25. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9(3):203-14.
26. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really $802 million? Health Aff (Millwood). 2006;25(2):420-8.
27. Kesselheim AS, Maggs LR, Sarpatwari A. Experience with the priority review voucher program for drug development. JAMA. 2015; 314(16):1687-8.
28. Kesselheim AS. Priority review vouchers: an inefficient and dangerous way to promote neglecteddisease drug development. Clin Pharmacol Ther. 2009;85(6):573-5.
29. Sonderholm J. In defence of priority review vouchers. Bioethics. 2009; 23(7):413-20.
30. Grabowski HG, DiMasi JA, Long G. The roles of patents and research and development incentives in biopharmaceutical innovation. Health Aff (Millwood). 2015;34(2):302-10.